CBD for Arthritis

Verdict: Oral CBD failed for arthritis pain

For arthritis, the best controlled trials show oral CBD works no better than placebo for joint pain, and at high doses it adds side effects rather than relief. It is graded counter-evidence: the marketed benefit has not held up in rigorous testing.

D 🔴 D Counter-Evidence Counter-Evidence

🔬Why this grade7-layer evidence engine

The grade reflects two adequately powered, double-blind randomized trials that both came up empty. A knee osteoarthritis trial adding 600 mg/day oral CBD to paracetamol found no extra pain relief over placebo (PMID 38033459, WOMAC difference negligible, p=0.80), while a hand osteoarthritis and psoriatic arthritis trial of 20-30 mg/day was likewise null (PMID 34510141, between-group difference 0.23 mm, p=0.96) with no benefit for sleep, anxiety, or depression.

The only positive randomized result was a tiny 18-person topical CBD crossover study of low strength (PMID 35637038), and the often-cited large benefit comes from an uncontrolled survey vulnerable to selection and recall bias (PMID 35999581). Two strong trials failing against placebo outweigh one small positive study and self-reported data, which is why the engine treats oral CBD for arthritis pain as counter-evidence rather than merely unproven.

Authoritative bodies reinforce this caution rather than contradict it. The US FDA has concluded CBD does not fit existing food or supplement frameworks; the UK Food Standards Agency advises healthy adults cap intake near 10 mg/day and warns vulnerable groups, including people on medication, to avoid it; and Mayo Clinic notes the widely promoted pain relief is unconfirmed and that CBD can cause side effects and drug interactions. The 600 mg trial also flagged more adverse events and liver-enzyme elevations, underscoring real risk without demonstrated arthritis benefit.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.44
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
D · Counter-Evidence
Confidence
79%
Broadly consistent
Evidence level
E6
Multiple smaller RCTs (n<500)

How strongly each layer supports this effect

lower = less supportive
L11 AI re-checkIndependent read
0.30
L5 Clinical bodiesAuthoritative stance
0.40
L2 PubMedPrimary literature
0.45
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.44
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — | C→D 因 scope.conflation_risk=true 且 L11 獨評較低 (B7-2 tier cap)
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Oral cannabidiol (CBD) as add-on to paracetamol for painful chronic osteoarthritis of the knee: a randomized, double-blind, placebo-controlled clinical trial
PMID: 38033459 2023 隨機對照試驗 n = 86
Finding: No additional analgesic effect of high-dose oral CBD over placebo. WOMAC pain reduction 2.5 (95% CI 1.8-3.3) with CBD vs 2.4 (95% CI 1.7-3.2) with placebo, p=0.80. Adverse events significantly more frequent with CBD (56% vs 44%, p=0.008); liver aminotransferase/GGT elevations more common with CBD (n=15 vs n=5, p=0.02).
⚠️ Industry-funded Effect size: Between-group WOMAC pain difference negligible; NS (p=0.80)
View on PubMed
Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind, placebo-controlled trial
PMID: 34510141 2022 隨機對照試驗 n = 129
Finding: Neither clinically nor statistically significant effect of CBD on pain. Between-group difference 0.23 mm (95% CI -9.41 to 9.90, p=0.96). Clinically meaningful pain reduction (>30 mm) seen in 22% CBD vs 21% placebo. No significant effect on sleep quality, depression, anxiety, or pain catastrophizing.
Government Effect size: Between-group pain difference 0.23 mm; NS (p=0.96)
View on PubMed
A Randomized Controlled Trial of Topical Cannabidiol for the Treatment of Thumb Basal Joint Arthritis
PMID: 35637038 2022 隨機對照試驗 n = 18
Finding: Topical CBD produced statistically significant improvements in thumb basal joint arthritis pain and disability versus control, with no adverse events. Positive but small single-center crossover trial.
🟠 Limited quality Effect size: Significant pain/disability improvement vs control (small n=18)
View on PubMed
Cannabidiol as a treatment for arthritis and joint pain: an exploratory cross-sectional study
PMID: 35999581 2022 Cross-sectional n = 428
Finding: Self-reported CBD use associated with improvements in pain (83%), physical function (66%), and sleep quality (66%); overall 44% pain reduction (p<0.001); osteoarthritis group reported greater reduction than RA. 60.5% reduced or stopped other medications. Observational design — subject to selection and recall bias, no placebo control.
🟠 Limited quality Effect size: Self-reported 44% pain reduction (uncontrolled)
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Against
Today, the U.S. Food and Drug Administration announced that the agency has concluded that a new regulatory pathway for CBD is needed... the agency has concluded that existing regulatory frameworks for foods and supplements are not appropriate for CBD. source↗
L4b EU EFSA
Against
L4c UK NHS
Cautious
Healthy adults should think carefully before taking CBD, and should consider limiting their consumption of CBD from food to no more than 10mg per day, which is about 4-5 drops of 5% CBD oil. The FSA continues to advise that CBD is not taken by people in vulnerable groups, including children, people taking medication and those who are pregnant or breastfeeding and those trying to conceive. source↗
L4d TW TFDA / 衛福部
Against
大麻二酚(CBD)不屬於毒品及管制藥品,考量其具有非常多藥理活性及可能的醫療用途,我國以一般藥品列管。 source↗
L4e WHO
Not addressed
In general, CBD is well tolerated with a good safety profile... To date, there is no evidence of recreational use of CBD or any public health-related problems associated with the use of pure CBD. [WHO ECDD Cannabidiol (CBD) Critical Review Report, June 2018] source↗
L5a NIH Office of Dietary Supplements
Cautious
L5b Mayo Clinic
Cautious
Early indicators show that it's safe, but many questions remain. CBD can cause side effects, including dry mouth, diarrhea, reduced appetite, drowsiness and fatigue. CBD can also interact with other medications. source↗
L5c Cleveland Clinic
Cautious
L5d Harvard Health
Cautious
L5e Specialty Society (condition-mapped)
Cautious
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-arthritis-INT-cannabidiol-001 繁體中文版 →